MAXCYTE, INC. Logo

MAXCYTE, INC.

Provides a scalable, non-viral electroporation platform for cell therapy development.

MXCT | US

Overview

Corporate Details

ISIN(s):
US57777K1060 (+2 more)
LEI:
54930053YHXULRFCU991
Country:
United States of America
Address:
9713 KEY WEST AVENUE,, 20850 ROCKVILLE
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

MaxCyte, Inc. is a commercial-stage cell-engineering company providing enabling platform technologies for the discovery, development, and commercialization of cell-based therapeutics. The company's core offering is its proprietary, non-viral Flow Electroporation® technology, delivered through the scalable ExPERT™ platform. This system facilitates high-efficiency engineering of complex cell types for a wide range of applications, including cell therapy, protein production, cell-based assays, and gene editing. In addition to its technology platform, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate gene editing safety. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-26 11:14
Director's Dealing
Correction: Vesting of RSUs and PDMR Dealing
English 57.0 KB
2025-03-26 08:00
Director's Dealing
Vesting of RSUs and PDMR Dealing
English 55.7 KB
2025-03-25 11:30
Major Shareholding Notification
Holding(s) in Company
English 88.0 KB
2025-03-25 11:28
Major Shareholding Notification
Holding(s) in Company
English 87.7 KB
2025-03-25 11:26
Major Shareholding Notification
Holding(s) in Company
English 87.8 KB
2025-03-25 11:22
Major Shareholding Notification
Holding(s) in Company
English 87.8 KB

Automate Your Workflow. Get a real-time feed of all MAXCYTE, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MAXCYTE, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MAXCYTE, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Isofol Medical Logo
Developing a drug to enhance chemotherapy efficacy for solid tumors like colorectal cancer.
Sweden
ISOFOL
IVIM Technology, Inc. Logo
Provides intravital microscopy systems & CRO services for preclinical research and drug discovery.
South Korea
460470
IXICO PLC Logo
AI-powered neuroimaging and biomarker analytics for neurological clinical trials.
United Kingdom
IXI
Jade Biosciences, Inc. Logo
Clinical-stage biotech developing therapies for autoimmune and inflammatory diseases.
United States of America
JBIO
Jasper Therapeutics, Inc. Logo
Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.
United States of America
JSPR
J. Molner AS Logo
A CDRO specializing in generic injectable and topical drugs for the North American market.
Estonia
JML
Kadimastem Ltd. Logo
Develops off-the-shelf stem cell therapies for diabetes & neurodegenerative diseases.
Israel
KDST
KAINOS MEDICINE, INC. Logo
Develops small molecule drugs for neurodegenerative diseases, cancers, and infectious diseases.
South Korea
284620
Kairos Pharma, LTD. Logo
Develops novel oncology therapies to reverse drug resistance and immune suppression.
United States of America
KAPA
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden
KAN

Talk to a Data Expert

Have a question? We'll get back to you promptly.